25 LLC’s AbbVie ABBV Stock Holding History

25 LLC’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-89	Closed	-$11.8K	–	39
2023 Q2	$11.8K	Sell	89 -6	-6%	-$880	0.01%	141
2023 Q1	$14K	Buy	+95	New	+$14.5K	0.01%	131

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

25 LLC's ABBV Position: Q3 2023 in Review

25 LLC sold out of AbbVie (ABBV) in Q3 2023, closing a stake of 89 shares — an estimated $11.8K sold.

25 LLC first reported a position in ABBV in Q1 2023 and held it in 2 quarters. The position peaked at $14K in Q1 2023. 3,108 funds tracked by Wall St. Rank hold ABBV as of Q3 2023.

25 LLC reported no remaining AbbVie position as of Q3 2023 after selling out during the quarter.
25 LLC sold 89 AbbVie shares in Q3 2023, an estimated $11.8K.
25 LLC first reported a position in AbbVie in Q1 2023 and held it in 2 quarters.
25 LLC's AbbVie position peaked at $14K in Q1 2023.
3,108 funds tracked by Wall St. Rank held AbbVie as of Q3 2023.

Based on 25 LLC's 13F filing for Q3 2023, filed 18 Oct 2023.